SCHEDULE: Frazier Life Sciences Discloses iBio Stake

Frazier Life Sciences entities report a combined 5.7% beneficial ownership in iBio, Inc. common stock as of March 31, 2026.

Summary

• Frazier Life Sciences Public Fund, L.P. (FLSPF) and related entities have filed a Schedule 13G amendment, reporting beneficial ownership of 1,953,467 shares of iBio, Inc. common stock.
• This holding represents 5.7% of the outstanding common stock as of February 9, 2026.
• The filing indicates that FLSPF directly holds 1,953,467 shares.
• Other Frazier Life Sciences entities, including FHMLSP, L.P., FHMLSP, L.L.C., Frazier Life Sciences XI, L.P., FHMLS XI, L.P., FHMLS XI, L.L.C., Frazier Life Sciences XII, L.P., FHMLS XII, L.P., and FHMLS XII, L.L.C., are also listed as reporting persons.
• These entities are organized in Delaware.
• The reported shares do not include certain pre-funded warrants, which are subject to beneficial ownership limitations of 9.99%.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it is a routine disclosure of beneficial ownership and does not provide new operational or financial information about iBio, Inc.

Positives

• Frazier Life Sciences Public Fund, L.P. directly holds a significant stake of 1,953,467 shares, representing 5.7% of iBio's common stock.
• The filing is an amendment to a Schedule 13G, indicating ongoing reporting and transparency from a major investor.

Negatives

• The filing does not contain financial performance data or operational updates for iBio, Inc., focusing solely on ownership disclosure.
• The beneficial ownership figures exclude pre-funded warrants, the exercise of which is capped by beneficial ownership limitations, suggesting potential future dilution or strategic considerations.

Risks

• The exercise of pre-funded warrants by FLSPF, FLS XI, and FLS XII is limited by a 9.99% beneficial ownership cap, which could restrict their ability to increase their stake or influence without triggering further disclosures or regulatory scrutiny.
• The complex structure of the reporting entities (L.P. and L.L.C. general partners) may obscure ultimate beneficial ownership and control, although the filing states no members of management committees are attributed beneficial ownership.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding iBio, Inc.'s future performance. It solely reports on beneficial ownership.

Industry Context

StockSavvy.ai notes that this Schedule 13G filing by Frazier Life Sciences indicates a significant investment in iBio, Inc., a company operating in the biotechnology sector. Such filings are common for institutional investors accumulating substantial stakes, often signaling confidence in the company's long-term prospects or potential for strategic influence.

Stakeholder Impact

• Shareholders: The disclosure confirms a significant institutional investor's stake, which could influence market perception and potential future strategic actions by iBio, Inc.
• Management: The reporting entities are investment funds, not operational management of iBio, Inc. Their role is primarily as investors.
• Creditors/Suppliers: No direct impact is indicated by this ownership filing.

Next Steps

• Monitor future filings from Frazier Life Sciences for any changes in beneficial ownership.
• Observe iBio, Inc.'s operational and financial performance for insights into the value of the investment.

Key Dates

Keywords

iBio, Inc., Schedule 13G, Frazier Life Sciences, Beneficial Ownership, Common Stock, SEC Filing, Investment Fund, Venture Capital, Healthcare, Biotechnology